Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sports guy, Auger08, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 11/23/2014 6:12:20 PM - Followers: 639 - Board type: Free - Posts Today: 3


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 

 

 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
PostSubject
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#76729   It is obvious, but I will say it anyways: elysse1kittycat 11/23/14 06:12:20 PM
#76728   Some green for ocat tommorrow. Gastrodamas 11/23/14 06:10:01 PM
#76727   Updated the big board, more data coming (financials Auger08 11/23/14 12:16:12 PM
#76726   Unfortunately, that's truly how I feel, as my farviewhill 11/22/14 10:26:12 PM
#76725   Realistic, but believe that it could be later. AyeEye 11/22/14 10:05:45 PM
#76724   Thanks Fuller, that seems to primarily be Wopsal's farviewhill 11/22/14 09:43:46 PM
#76723   Thanks, Wopsal. farviewhill 11/22/14 09:25:45 PM
#76722   I read that it was mentioned by management homeslice10 11/22/14 08:29:30 PM
#76721   My guess is they wait til January because fulleroots 11/22/14 08:13:38 PM
#76720   My guess is they use shares from the Wopsal101 11/22/14 07:15:44 PM
#76719   FULLER, any thoughts on how they will meet farviewhill 11/22/14 06:46:16 PM
#76718   Thanks WOPSAL. That helps and has a farviewhill 11/22/14 06:44:23 PM
#76717   Yes i think they will shortly . fulleroots 11/22/14 06:17:49 PM
#76716   Fairview, the comments from management were at the Wopsal101 11/22/14 06:12:50 PM
#76715   AYEEYE, I didn't personally hear or see it, farviewhill 11/22/14 03:46:24 PM
#76714   Thanks Chuck! AyeEye 11/22/14 03:30:34 PM
#76713   AyeEye Here are the OCAT comments from Icell. chuckanutman 11/22/14 01:59:09 PM
#76712   Doubt it. Nasdaq Global Select Market (standard AyeEye 11/22/14 01:49:17 PM
#76711   OCAT Up-list to NAS in 2014 then Platelets/JV. chuckanutman 11/22/14 12:08:44 PM
#76710   In addition to all of the nefarious forces elysse1kittycat 11/22/14 09:09:06 AM
#76709   Paul Wotton did not leave a thriving antares Gastrodamas 11/22/14 08:47:03 AM
#76708   Well lets just say that hopefully they have elysse1kittycat 11/21/14 11:04:44 PM
#76707   Looking at things retrospectively or as they say, elysse1kittycat 11/21/14 11:01:15 PM
#76706   We all knew that once the vote passed Gastrodamas 11/21/14 10:59:50 PM
#76705   Management has their money and plenty of shares Gastrodamas 11/21/14 10:56:25 PM
#76704   Then ART, I believe an honest question can farviewhill 11/21/14 10:52:27 PM
#76703   The 'problem' FERN is, while it's incubating, we're farviewhill 11/21/14 10:25:27 PM
#76702   That's so true and I've posted similar thoughts farviewhill 11/21/14 10:21:17 PM
#76701   Farv thanks for post brother sports guy 11/21/14 07:57:39 PM
#76700   Your PM is how I feel these days, farviewhill 11/21/14 05:09:51 PM
#76699   I concur. Also, would it be reasonable to Fern Wood 11/21/14 05:00:37 PM
#76698   >>OCAT: The progress of the original condition was art2426 11/21/14 04:50:30 PM
#76697   For that matter so would men with interests/concerns elysse1kittycat 11/21/14 04:48:03 PM
#76696   BTW would you happen to know who our Killtoy 11/21/14 04:38:39 PM
#76695   All the girls with the BOBs would be interested... Killtoy 11/21/14 04:30:49 PM
#76694   LOL Fern Wood 11/21/14 04:12:08 PM
#76693   How about naming the long lasting battery that elysse1kittycat 11/21/14 04:03:24 PM
#76692   YUP TGIF AND THANKS TO IHUB ITS HAPPY sports guy 11/21/14 03:58:35 PM
#76691   yeah, the bionic solution probably requires batteries....that eventually Fern Wood 11/21/14 03:57:02 PM
#76690   You know even though we know that the elysse1kittycat 11/21/14 02:58:09 PM
#76689   never too late bro fulleroots 11/21/14 02:20:34 PM
#76688   Imo other than when cc's and shareholder meetings elysse1kittycat 11/21/14 01:53:15 PM
#76687   Do blind people have a right to see? chuckanutman 11/21/14 12:42:31 PM
#76686   Im one of the not to smart ones Killtoy 11/21/14 12:38:01 PM
#76685   i agree im not a big fan of fulleroots 11/21/14 12:16:53 PM
#76684   You might be right majority out there rather Killtoy 11/21/14 12:15:08 PM
#76683   No guarantee but my gut instinct tells me elysse1kittycat 11/21/14 12:04:27 PM
#76681   YUP and everyone if you are smart should fulleroots 11/21/14 10:52:33 AM
#76680   yeah i know i am beating a dead fulleroots 11/21/14 10:49:56 AM
#76678   is this not normal, ceo's getting rich? guy3 11/21/14 10:37:20 AM
PostSubject